lonamo duo 50 mg + 850 mg tabletki powlekane
egis pharmaceuticals plc - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
asigefort 50 mg + 850 mg tabletki powlekane
tad pharma gmbh - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
asigefort 50 mg + 1000 mg tabletki powlekane
tad pharma gmbh - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
mifomet 50 mg + 1000 mg tabletki powlekane
bausch health poland sp. z o.o. - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
mifomet 50 mg + 850 mg tabletki powlekane
bausch health poland sp. z o.o. - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
maymetsi 50 mg + 850 mg tabletki powlekane
krka, d.d., novo mesto - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
maymetsi 50 mg + 1000 mg tabletki powlekane
krka, d.d., novo mesto - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
sitagliptin aflofarm 100 mg tabletki powlekane
aflofarm farmacja polska sp. z o.o. - sitagliptini hydrochloridum monohydricum - tabletki powlekane - 100 mg
onglyza
astrazeneca ab - Саксаглиптин - diabetes mellitus, type 2 - leki stosowane w cukrzycy - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
saxotin 50 mg tabletki
sandoz gmbh - vildagliptinum - tabletki - 50 mg